Retro Biosciences
artifactAI & Compute · Biotech & Transhumanism
One of tech's biggest names is betting nearly a billion dollars that AI can add ten healthy years to your life.
Who they are
Retro Biosciences, a biotech startup backed by OpenAI's Sam Altman[1].
What they do
The engine treats it as an attempt to use AI to reverse cellular aging and extend the healthy human lifespan.
How it works
Altman put in $180 million in 2022, and OpenAI deployed a biology-focused AI called GPT-4b micro that treats protein sequences like a programming language; it redesigned the 'Yamanaka factors' used to rejuvenate cells and got a reported 50-fold jump in efficiency. The startup went from that $180M seed to a $1B Series A at a $5B valuation.
Why it matters
It matters because it puts control over directed biological aging in the hands of one AI-owning company, a private grip on the technology of staying young.
The engine's record — word for word
Biotechnology startup. Altman invested $180M (2022). Aims to extend healthy human lifespan by 10 years through cellular reprogramming, autophagy, plasma-inspired therapeutics. OpenAI deployed GPT-4b micro — biology-focused AI treating protein sequences as programmable language. Redesigned Yamanaka factors (RetroSOX, RetroKLF) achieving 50-fold increase in cellular reprogramming efficiency. AI-driven biological engineering achieving results traditional science cannot match at scale.
Report #60: GPT-4b micro achieved 50x efficiency in Yamanaka factor redesign. $180M→$1B Series A at $5B valuation. Captive AI monopoly over directed biological evolution.
Follow the trail
Walk this on the live map →